Seer, Inc. (SEER)
| Market Cap | 120.71M-3.1% |
| Revenue (ttm) | 14.22M |
| Net Income | -67.96M |
| EPS | -1.22 |
| Shares Out | 55.37M |
| PE Ratio | n/a |
| Forward PE | -2.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,346 |
| Open | 2.21 |
| Previous Close | 2.21 |
| Day's Range | 2.17 - 2.21 |
| 52-Week Range | 1.55 - 2.41 |
| Beta | 1.47 |
| Analysts | none |
| Price Target | 4.00(+83.49%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SEER
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SEER stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SEER holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SEER's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SEER Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SEER Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Stock-based compensation | $1.56M | 72.41% |
| Other | $596.00K | 27.59% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SEER patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SEER from public contracts
Source: USAspending.gov
SEER Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SEER’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score